Adalvo proudly joins the global initiative to raise awareness on heart health, as the world marks World Heart Day on Friday, September 29th.
Adalvo is deeply committed to cardiovascular health, and our portfolio of innovative cardiovascular products reflects this dedication. In 2022, our cardiovascular products collectively achieved remarkable sales totaling$43.7BN, according to IMS data. Our cardiovascular product dossier, offering a substantial impact on global health includes, but is not limited to:
Our hybrid/505b2 product, the combination of Rosuvastatin and Candesartan, holds great promise. The projected sales is expected to reach $900MN by 2028, offering innovative therapeutic options to patients globally.
On this World Heart Day, Adalvo reaffirms its unwavering commitment to advancing cardiovascular health through pioneering research and development.
Adalvo will continue to grow their portfolio offerings in this domain, further highlighting our ability to offer differentiated, value-added products to our partners.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!